56
Participants
Start Date
December 11, 2012
Primary Completion Date
February 11, 2021
Study Completion Date
March 11, 2021
Neratinib
Fulvestrant
Trastuzumab
Tumor biopsy
-Optional at baseline and disease progression
Research blood sample
-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
University of North Carolina at Chapel Hill (Lineberger Comprehensive Cancer Center), Chapel Hill
Duke Cancer Institute at Duke University Medical Center, Durham
University of Miami Hospital and Clinics, Miami
University of Alabama Cancer Center, Birmingham
University of Michigan, Ann Arbor
Avera Cancer Institute, Sioux Falls
Northwestern University - Feinberg School of Medicine, Chicago
Rush University Medical Center, Chicago
Washington University School of Medicine, St Louis
St. Luke's Cancer Institute, Kansas City
Baylor College of Medicine, Houston
Mayo Clinic, Phoenix
University of Southern California Keck School of Medicine, Los Angeles
Stanford Medicine Cancer Institute, Stanford
Dana-Farber Cancer Institute, Harvard University, Boston
BC Cancer Agency, Vancouver
Princess Margaret Cancer Centre, Toronto
Puma Biotechnology, Inc.
INDUSTRY
United States Department of Defense
FED
Washington University School of Medicine
OTHER